When Was Mounjaro Invented — and How Long Did It Take to Reach the UK?

What scientific problem was tirzepatide designed to solve?

The starting point was a frustration familiar to metabolic researchers: existing medicines that targeted only the GLP-1 receptor worked well, but a second gut hormone called GIP (glucose-dependent insulinotropic polypeptide) appeared to play an equally important role in appetite regulation and fat metabolism. GIP had long been considered a less useful target, partly because people with type 2 diabetes appeared to respond to it differently. Eli Lilly's researchers challenged that assumption in the early 2000s, asking whether the two pathways together might be meaningfully more effective than either alone.

That hypothesis drove years of preclinical work. By the early 2010s the company had designed a single synthetic molecule capable of binding both the GIP receptor and the GLP-1 receptor, tirzepatide. Patent filings followed around 2012–2013, locking in the compound's structure and beginning the formal development process. You can read more about the scientists credited with that work on the people behind Mounjaro's invention page.

The practical upshot of the dual mechanism is that tirzepatide slows how quickly the stomach empties, increases feelings of fullness after eating, and helps the body respond to insulin more efficiently. The NHS describes this combined action as the reason tirzepatide sits in a different pharmacological category from the GLP-1-only medicines that came before it, and it is described in detail on the tirzepatide overview page.

When did clinical trials for tirzepatide begin, and what did they show?

Phase 1 studies, which test safety and dosing in small groups of healthy volunteers, took place through the mid-2010s. Larger-scale trials in people with type 2 diabetes (the SURPASS programme) began around 2018 and 2019. Weight-management trials under the separate SURMOUNT banner started in 2019, with SURMOUNT-1 recruiting 2,539 adults with obesity but without diabetes.

SURMOUNT-1's 72-week results were published in the New England Journal of Medicine in 2022, reporting average body-weight reductions of around 20–21% at the highest dose. Those figures attracted considerable attention because they exceeded what had been seen with single-pathway medicines in comparable trials. For context on how the results compare with semaglutide data, the Mounjaro cost and treatment context page covers the clinical background alongside pricing information.

A head-to-head comparison, SURMOUNT-5, was published in the New England Journal of Medicine in 2025 and found that tirzepatide produced greater average weight reduction than semaglutide 2.4mg over 72 weeks in adults with obesity and no diabetes, the most direct comparison the field had produced. NICE referenced that evidence in its December 2024 technology appraisal of tirzepatide, TA1026, which recommended tirzepatide for eligible adults in England.

When was Mounjaro actually released, and how did it arrive in the UK?

Regulatory timelines varied by country. The FDA approved tirzepatide for type 2 diabetes in the United States in May 2022 under the brand name Mounjaro, and for obesity in November 2023 as Zepbound, a brand that does not exist in the UK, where tirzepatide is sold solely as Mounjaro regardless of indication. The fuller account of the UK release chronology is on the when Mounjaro was released in the UK page.

In the UK, the MHRA granted marketing authorisation for Mounjaro in November 2023 for weight management, and separately it had already been authorised for type 2 diabetes. Eli Lilly then made it available to UK private prescribers fairly quickly, though NHS access followed a longer commissioning process. NICE published TA1026 in December 2024, and NHS England began phased access from June 2025, a process still unfolding as cohort criteria expand.

For anyone wondering about timing in a very practical sense: because Mounjaro requires a fresh clinical assessment before each supply, there is no single "best" moment to start beyond when it suits you medically. Orders placed by noon on a weekday, including Monday mornings or the week after a bank holiday, are reviewed the same day by a GPhC-registered prescriber and dispatched for next-working-day delivery, so a week away or a busy patch at work need not delay the process unduly.

Does the age of the research affect how confident we can be in Mounjaro today?

Two decades of development, including years of large-scale trials involving thousands of participants, means tirzepatide now has one of the more substantial pre-licence evidence bases among weight-management medicines. That said, Mounjaro still carries a Black Triangle (▼) designation from the MHRA, which means it is subject to additional post-market monitoring, a standard step for newer medicines, not a signal of concern, but a reason the regulator continues to collect real-world data.

What that means practically is that the prescriber reviewing your consultation is working with both the trial evidence and emerging post-market information. Questions about how tirzepatide behaves over time, what to expect dose by dose, and when stopping Mounjaro might be appropriate are all things our prescribers can address directly. Side effects in the trial data were predominantly gastrointestinal (nausea, loose stools, constipation and similar) generally settling as the body adjusted; details are on the digestive effects page for anyone who wants a closer look at that part of the picture.

If you are thinking about whether tirzepatide might be right for you, the free consultation at nume is the place to check your eligibility with a prescriber.